Julie B. Feder is CFO at Aura Biosciences, Inc. (AURA). They have made 2 open-market trades across 1 company since 2022, most recently 2024-10-18.
CIK 0001710237
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AURA | 134,276 | $820K |
Shares reported on the most recent Form 4, priced at the 2024-10-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AURA | SELL · 10b5-1 | 2024-10-18 | 2024-10-21 | $12.03 | $605K | -10.4% | -24.9% | -31.9% |
| AURA | SELL | 2024-01-23 | 2024-01-24 | $7.64 | $101K | +2.9% | +17.7% | -4.4% |
| AURA | SELL · 10b5-1 | 2023-11-06 | 2023-11-07 | $12.07 | $47K | +6.9% | +13.9% | +2.5% |
| AURA | SELL | 2023-10-30 | 2023-11-01 | $6.82 | $23K | -14.5% | -9.7% | -10.5% |
| AURA | SELL · 10b5-1 | 2022-10-31 | 2022-11-02 | $12.45 | $25K | +6.4% | +7.1% | -15.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.